Login to Your Account



NLS phase II results advance effort to carve out alternative ADHD drug niche

By Michael Fitzhugh
Staff Writer

Thursday, June 1, 2017

NLS Pharma Group’s lead compound, NLS-1 (mazindol), more than halved a common measure of attention deficit hyperactivity disorder (ADHD) symptoms in 55 percent of treated adults vs. 15.8 percent of placebo-treated subjects in a randomized phase II trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription